Morphic Announces Participation in Upcoming Investor Conferences
16 nov. 2021 09h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
15 nov. 2021 09h05 HE
|
Morphic Therapeutic
αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...
Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Morphic Therapeutic
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced appointment of Nisha Nanda, Ph.D.,...
Morphic to Participate in Jefferies IBD Therapeutics Summit
12 oct. 2021 16h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Participation in September Investor Conferences
01 sept. 2021 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
23 août 2021 16h01 HE
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results
04 août 2021 07h00 HE
|
Morphic Therapeutic
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22 Presented positive preclinical data from αvβ8 program at AACR...
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
09 juil. 2021 06h35 HE
|
Morphic Therapeutic
MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset...
Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021
02 juil. 2021 09h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO’21 Virtual Congress
28 mai 2021 08h00 HE
|
Morphic Therapeutic
Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens...